<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37133535</PMID><DateCompleted><Year>2023</Year><Month>07</Month><Day>17</Day></DateCompleted><DateRevised><Year>2023</Year><Month>07</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1432-1459</ISSN><JournalIssue CitedMedium="Internet"><Volume>270</Volume><Issue>8</Issue><PubDate><Year>2023</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Journal of neurology</Title><ISOAbbreviation>J Neurol</ISOAbbreviation></Journal><ArticleTitle>Genetic characterization of primary lateral sclerosis.</ArticleTitle><Pagination><StartPage>3970</StartPage><EndPage>3980</EndPage><MedlinePgn>3970-3980</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00415-023-11746-7</ELocationID><Abstract><AbstractText Label="BACKGROUND AND OBJECTIVES" NlmCategory="OBJECTIVE">Primary lateral sclerosis (PLS) is a motor neuron disease characterised by loss of the upper motor neurons. Most patients present with slowly progressive spasticity of the legs, which may also spread to the arms or bulbar regions. It is challenging to distinguish between PLS, early-stage amyotrophic lateral sclerosis (ALS) and hereditary spastic paraplegia (HSP). The current diagnostic criteria advise against extensive genetic testing. This recommendation is, however, based on limited data.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We aim to genetically characterize a PLS cohort using whole exome sequencing (WES) for genes associated with ALS, HSP, ataxia and movement disorders (364 genes) and C9orf72 repeat expansions. Patients fulfilling the definite PLS criteria by Turner et al. and with available DNA samples of sufficient quality were recruited from an on-going, population-based epidemiological study. Genetic variants were classified according to the ACMG criteria and assigned to groups based on disease association.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">WES was performed in 139 patients and the presence of repeat expansions in C9orf72 was analysed separately in 129 patients. This resulted in 31 variants of which 11 were (likely) pathogenic. (Likely) pathogenic variants resulted in 3 groups based on disease association: ALS-FTD (C9orf72, TBK1), pure HSP (SPAST, SPG7), "ALS-HSP-CMT overlap" (FIG4, NEFL, SPG11).</AbstractText><AbstractText Label="DISCUSSION" NlmCategory="CONCLUSIONS">In a cohort of 139 PLS patients, genetic analyses resulted in 31 variants (22%) of which 10 (7%) (likely) pathogenic associated with different diseases (predominantly ALS and HSP). Based on these results and the literature, we advise to consider genetic analyses in the diagnostic work-up for PLS.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>de Boer</LastName><ForeName>Eva M J</ForeName><Initials>EMJ</Initials><Identifier Source="ORCID">0000-0002-2629-2748</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Brain Center Rudolf Magnus, University Medical Center Utrecht, Utrecht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Vries</LastName><ForeName>Balint S</ForeName><Initials>BS</Initials><AffiliationInfo><Affiliation>Department of Neurology, Brain Center Rudolf Magnus, University Medical Center Utrecht, Utrecht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pennings</LastName><ForeName>Maartje</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-5485-7497</Identifier><AffiliationInfo><Affiliation>Department of Human Genetics, Radboud University Medical Center, Nijmegen, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kamsteeg</LastName><ForeName>Erik-Jan</ForeName><Initials>EJ</Initials><Identifier Source="ORCID">0000-0001-6480-1892</Identifier><AffiliationInfo><Affiliation>Department of Human Genetics, Radboud University Medical Center, Nijmegen, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Veldink</LastName><ForeName>Jan H</ForeName><Initials>JH</Initials><Identifier Source="ORCID">0000-0001-5572-9657</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Brain Center Rudolf Magnus, University Medical Center Utrecht, Utrecht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van den Berg</LastName><ForeName>Leonard H</ForeName><Initials>LH</Initials><Identifier Source="ORCID">0000-0002-5203-9674</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Brain Center Rudolf Magnus, University Medical Center Utrecht, Utrecht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Es</LastName><ForeName>Michael A</ForeName><Initials>MA</Initials><Identifier Source="ORCID">0000-0002-7709-5883</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Brain Center Rudolf Magnus, University Medical Center Utrecht, Utrecht, The Netherlands. m.a.vanes@umcutrecht.nl.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>05</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>J Neurol</MedlineTA><NlmUniqueID>0423161</NlmUniqueID><ISSNLinking>0340-5354</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000073885">C9orf72 Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 5.6.1.1</RegistryNumber><NameOfSubstance UI="C400283">SPAST protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.6.4.3</RegistryNumber><NameOfSubstance UI="D000074181">Spastin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C520412">SPG11 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011506">Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.1.3.-</RegistryNumber><NameOfSubstance UI="C522215">FIG4 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005420">Flavoproteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.1.3.2</RegistryNumber><NameOfSubstance UI="D010744">Phosphoric Monoester Hydrolases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000073885" MajorTopicYN="N">C9orf72 Protein</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057180" MajorTopicYN="Y">Frontotemporal Dementia</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016472" MajorTopicYN="Y">Motor Neuron Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009046" MajorTopicYN="N">Motor Neurons</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000074181" MajorTopicYN="N">Spastin</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011506" MajorTopicYN="N">Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005420" MajorTopicYN="N">Flavoproteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010744" MajorTopicYN="N">Phosphoric Monoester Hydrolases</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">Genetics</Keyword><Keyword MajorTopicYN="N">Hereditary spastic paraplegia</Keyword><Keyword MajorTopicYN="N">Primary lateral sclerosis</Keyword></KeywordList><CoiStatement>Jan Veldink reports to have sponsored research agreements with Biogen and Astra Zeneca. Leonard van den Berg declares fees to his institution from Biogen, Wave, Amylyx, Ferrer, and Cytokinetics for being on a scientific advisory board; fees to his institution from Amylyx for a lecture; an unrestricted educational grant from Takeda, and is the Chair of ENCALS and TRICALS. Michael van Es has consulted for Biogen, and has received travel grants from Shire (formerly Baxalta), performs work as a medical monitor for an on-going trial from Ferrer (NCT05178810).</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>2</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>4</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>4</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>7</Month><Day>17</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>5</Month><Day>3</Day><Hour>12</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>5</Month><Day>3</Day><Hour>11</Hour><Minute>5</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37133535</ArticleId><ArticleId IdType="pmc">PMC10345048</ArticleId><ArticleId IdType="doi">10.1007/s00415-023-11746-7</ArticleId><ArticleId IdType="pii">10.1007/s00415-023-11746-7</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Statland JM, Barohn RJ, Dimachkie MM, Floeter MK, Mitsumoto H. Primary lateral sclerosis. Neurol Clin. 2015;33:749&#x2013;760. doi: 10.1016/j.ncl.2015.07.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ncl.2015.07.007</ArticleId><ArticleId IdType="pmc">PMC4628724</ArticleId><ArticleId IdType="pubmed">26515619</ArticleId></ArticleIdList></Reference><Reference><Citation>van Es MA, Hardiman O, Chio A, Al-Chalabi A, Pasterkamp RJ, Veldink JH, et al. Amyotrophic lateral sclerosis. The Lancet. 2017;390:2084&#x2013;2098. doi: 10.1016/S0140-6736(17)31287-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(17)31287-4</ArticleId><ArticleId IdType="pubmed">28552366</ArticleId></ArticleIdList></Reference><Reference><Citation>De Vries BS, Rustemeijer LMM, Bakker LA, Schr&#xf6;der CD, Veldink JH, Van Den Berg LH, et al. Cognitive and behavioural changes in PLS and PMA: challenging the concept of restricted phenotypes. J Neurol Neurosurg Psychiatry. 2019;90:141&#x2013;147. doi: 10.1136/jnnp-2018-318788.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2018-318788</ArticleId><ArticleId IdType="pubmed">30076267</ArticleId></ArticleIdList></Reference><Reference><Citation>de Vries BS, Spreij LA, Rustemeijer LMM, Bakker LA, Veldink JH, van den Berg LH, et al. A neuropsychological and behavioral study of PLS. Amyotroph Lateral Scler Frontotemporal Degener. 2019;20:376&#x2013;384. doi: 10.1080/21678421.2019.1620284.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2019.1620284</ArticleId><ArticleId IdType="pubmed">31134825</ArticleId></ArticleIdList></Reference><Reference><Citation>Finegan E, Chipika RH, Shing SLH, Hardiman O, Bede P. Primary lateral sclerosis: a distinct entity or part of the ALS spectrum? Amyotroph Lateral Scler Frontotemporal Degener. 2019;20:133&#x2013;145. doi: 10.1080/21678421.2018.1550518.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2018.1550518</ArticleId><ArticleId IdType="pubmed">30654671</ArticleId></ArticleIdList></Reference><Reference><Citation>Pringle CE, Hudson AJ, Munoz DG, Kiernan JA, Brown WF, Ebers GC. Primary lateral sclerosis clinical features, neuropathology and diagnostic criteria. Brain. 1992;115:495&#x2013;520. doi: 10.1093/brain/115.2.495.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/115.2.495</ArticleId><ArticleId IdType="pubmed">1606479</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon PH, Cheng B, Katz IB, Pinto M, Hays AP, Mitsumoto H, et al. The natural history of primary lateral sclerosis. Neurology. 2006;66:647&#x2013;653. doi: 10.1212/01.wnl.0000200962.94777.71.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000200962.94777.71</ArticleId><ArticleId IdType="pubmed">16534101</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner MR, Barohn RJ, Corcia P, Fink JK, Harms MB, Kiernan MC, et al. Primary lateral sclerosis: consensus diagnostic criteria. J Neurol Neurosurg Psychiatry. 2020;91:373&#x2013;377. doi: 10.1136/jnnp-2019-322541.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2019-322541</ArticleId><ArticleId IdType="pmc">PMC7147236</ArticleId><ArticleId IdType="pubmed">32029539</ArticleId></ArticleIdList></Reference><Reference><Citation>Krzosek P, Madetko N, Migda A, Migda B, Jagu&#x15b; D, Alster P. Differential diagnosis of rare subtypes of progressive supranuclear palsy and PSP-like syndromes&#x2014;infrequent manifestations of the most common form of atypical parkinsonism. Front Aging Neurosci. 2022;14:1&#x2013;9. doi: 10.3389/fnagi.2022.804385.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnagi.2022.804385</ArticleId><ArticleId IdType="pmc">PMC8864174</ArticleId><ArticleId IdType="pubmed">35221993</ArticleId></ArticleIdList></Reference><Reference><Citation>de Souza PVS, de Rezende Pinto WBV, de Rezende Batistella GN, Bortholin T, Oliveira ASB. Hereditary spastic paraplegia: clinical and genetic hallmarks. Cerebellum. 2017;16:525&#x2013;551. doi: 10.1007/s12311-016-0803-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12311-016-0803-z</ArticleId><ArticleId IdType="pubmed">27271711</ArticleId></ArticleIdList></Reference><Reference><Citation>Erfanian Omidvar M, Torkamandi S, Rezaei S, Alipoor B, Omrani MD, Darvish H, et al. Genotype&#x2013;phenotype associations in hereditary spastic paraplegia: a systematic review and meta-analysis on 13,570 patients. J Neurol. 2021;268:2065&#x2013;2082. doi: 10.1007/s00415-019-09633-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-019-09633-1</ArticleId><ArticleId IdType="pubmed">31745725</ArticleId></ArticleIdList></Reference><Reference><Citation>McDermott CJ, White K, Bushby K, Shaw PJ. Hereditary spastic paraparesis: a review of new developments. J Neurol Neurosurg Psychiatry. 2000;69:150&#x2013;160. doi: 10.1136/jnnp.69.2.150.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.69.2.150</ArticleId><ArticleId IdType="pmc">PMC1737070</ArticleId><ArticleId IdType="pubmed">10896685</ArticleId></ArticleIdList></Reference><Reference><Citation>Pennings M, Schouten MI, van Gaalen J, Meijer RPP, de Bot ST, Kriek M, et al. KIF1A variants are a frequent cause of autosomal dominant hereditary spastic paraplegia. Eur J Hum Genet. 2020;28:40&#x2013;49. doi: 10.1038/s41431-019-0497-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41431-019-0497-z</ArticleId><ArticleId IdType="pmc">PMC6906463</ArticleId><ArticleId IdType="pubmed">31488895</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu N, Chen J, Xu C, Shi T, Li J. Hereditary spastic paraplegia associated with a rare IFIH1 mutation: a case report and literature review. Hereditas. 2019;156:28. doi: 10.1186/s41065-019-0104-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s41065-019-0104-x</ArticleId><ArticleId IdType="pmc">PMC6693153</ArticleId><ArticleId IdType="pubmed">31427910</ArticleId></ArticleIdList></Reference><Reference><Citation>Rovito C, Paganoni S, Babu S, Tenforde AS. Improved function in a runner with hereditary spastic paraparesis with use of extracorporeal shockwave therapy: personal clinical experience. Am J Phys Med Rehabil. 2021;100:e66&#x2013;e68. doi: 10.1097/PHM.0000000000001547.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/PHM.0000000000001547</ArticleId><ArticleId IdType="pubmed">32732747</ArticleId></ArticleIdList></Reference><Reference><Citation>Mereaux JL, Banneau G, Papin M, Coarelli G, Valter R, Raymond L, et al. Clinical and genetic spectra of 1550 index patients with hereditary spastic paraplegia. Brain. 2022;145:1029&#x2013;1037. doi: 10.1093/brain/awab386.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awab386</ArticleId><ArticleId IdType="pubmed">34983064</ArticleId></ArticleIdList></Reference><Reference><Citation>Huisman MHB, De Jong SW, Van Doormaal PTC, Weinreich SS, Schelhaas HJ, Van Der Kooi AJ, et al. Population based epidemiology of amyotrophic lateral sclerosis using capture-recapture methodology. J Neurol Neurosurg Psychiatry. 2011;82:1165&#x2013;1170. doi: 10.1136/jnnp.2011.244939.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.2011.244939</ArticleId><ArticleId IdType="pubmed">21622937</ArticleId></ArticleIdList></Reference><Reference><Citation>Abrahams S, Newton J, Niven E, Foley J, Bak TH. Screening for cognition and behaviour changes in ALS. Amyotroph Lateral Scler Frontotemporal Degener. 2014;15:9&#x2013;14. doi: 10.3109/21678421.2013.805784.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2013.805784</ArticleId><ArticleId IdType="pubmed">23781974</ArticleId></ArticleIdList></Reference><Reference><Citation>Dubois B, Slachevsky A, Litvan I, Pillon B. The FAB: a frontal assessment battery at bedside. Neurology. 2000;55:1621. doi: 10.1212/WNL.55.11.1621.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.55.11.1621</ArticleId><ArticleId IdType="pubmed">11113214</ArticleId></ArticleIdList></Reference><Reference><Citation>Raaphorst J, Beeldman E, Schmand B, Berkhout J, Linssen WHJP, Van Den Berg LH et al. (2012) The ALS-FTD-Q A new screening tool for behavioral disturbances in ALS</Citation><ArticleIdList><ArticleId IdType="pubmed">22972650</ArticleId></ArticleIdList></Reference><Reference><Citation>von Elm E, Altman DG, Egger M, Pocock SJ, G&#xf8;tzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol. 2008;61:344&#x2013;349. doi: 10.1016/j.jclinepi.2007.11.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jclinepi.2007.11.008</ArticleId><ArticleId IdType="pubmed">18313558</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Sanden BPGH, Corominas J, de Groot M, Pennings M, Meijer RPP, Verbeek N, et al. Systematic analysis of short tandem repeats in 38,095 exomes provides an additional diagnostic yield. Genet Med. 2021;23:1569&#x2013;1573. doi: 10.1038/s41436-021-01174-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41436-021-01174-1</ArticleId><ArticleId IdType="pubmed">33846582</ArticleId></ArticleIdList></Reference><Reference><Citation>Neveling K, Feenstra I, Gilissen C, Hoefsloot LH, Kamsteeg EJ, Mensenkamp AR, et al. A Post-hoc comparison of the utility of sanger sequencing and exome sequencing for the diagnosis of heterogeneous diseases. Hum Mutat. 2013;34:1721&#x2013;1726. doi: 10.1002/humu.22450.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/humu.22450</ArticleId><ArticleId IdType="pubmed">24123792</ArticleId></ArticleIdList></Reference><Reference><Citation>Sequeiros J, Seneca S, Martindale J. Consensus and controversies in best practices for molecular genetic testing of spinocerebellar ataxias. Eur J Hum Genet. 2010;18:1188&#x2013;1195. doi: 10.1038/ejhg.2010.10.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ejhg.2010.10</ArticleId><ArticleId IdType="pmc">PMC2987480</ArticleId><ArticleId IdType="pubmed">20179748</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Rheenen W, Van Blitterswijk M, Huisman MHB, Vlam L, Van Doormaal PTC, Seelen M, et al. Hexanucleotide repeat expansions in C9ORF72 in the spectrum of motor neuron diseases. Neurology. 2012;79:878&#x2013;882. doi: 10.1212/WNL.0b013e3182661d14.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e3182661d14</ArticleId><ArticleId IdType="pubmed">22843265</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Mossevelde S, van der Zee J, Cruts M, Van Broeckhoven C. Relationship between C9orf72 repeat size and clinical phenotype. Curr Opin Genet Dev. 2017;44:117&#x2013;124. doi: 10.1016/j.gde.2017.02.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.gde.2017.02.008</ArticleId><ArticleId IdType="pubmed">28319737</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamsteeg EJ, Kress W, Catalli C, Hertz JM, Witsch-Baumgartner M, Buckley MF, et al. Best practice guidelines and recommendations on the molecular diagnosis of myotonic dystrophy types 1 and 2. Eur J Hum Genet. 2012;20:1203&#x2013;1208. doi: 10.1038/ejhg.2012.108.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ejhg.2012.108</ArticleId><ArticleId IdType="pmc">PMC3499739</ArticleId><ArticleId IdType="pubmed">22643181</ArticleId></ArticleIdList></Reference><Reference><Citation>Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genetic Med. 2015;17:405&#x2013;424. doi: 10.1038/gim.2015.30.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/gim.2015.30</ArticleId><ArticleId IdType="pmc">PMC4544753</ArticleId><ArticleId IdType="pubmed">25741868</ArticleId></ArticleIdList></Reference><Reference><Citation>Bethesda (MD): National Library of Medicine (US) NC for BI. Gene [Internet] n.d. https://www.ncbi.nlm.nih.gov/gene. Accessed 25 Aug 2022</Citation></Reference><Reference><Citation>Strong MJ, Abrahams S, Goldstein LH, Woolley S, Mclaughlin P, Snowden J, et al. disorder (ALS-FTSD): revised diagnostic criteria. Amyotroph Lateral Scler Frontotemporal Degener. 2017;18:153&#x2013;174. doi: 10.1080/21678421.2016.1267768.Amyotrophic.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2016.1267768.Amyotrophic</ArticleId><ArticleId IdType="pmc">PMC7409990</ArticleId><ArticleId IdType="pubmed">28054827</ArticleId></ArticleIdList></Reference><Reference><Citation>Lachtermacher MBR, Seu&#xe1;nez HN, Moser AB, Moser HW, Smith KD. Determination of 30 X-linked adrenoleukodystrophy mutations, including 15 not previously described. Hum Mutat. 2000;15:348&#x2013;353. doi: 10.1002/(SICI)1098-1004(200004)15:4&lt;348::AID-HUMU7&gt;3.0.CO;2-N.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/(SICI)1098-1004(200004)15:4&lt;348::AID-HUMU7&gt;3.0.CO;2-N</ArticleId><ArticleId IdType="pubmed">10737980</ArticleId></ArticleIdList></Reference><Reference><Citation>Silani V, Corcia P, Harms MB, Rouleau G, Siddique T, Ticozzi N. Genetics of primary lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2020;21:28&#x2013;34. doi: 10.1080/21678421.2020.1837177.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2020.1837177</ArticleId><ArticleId IdType="pubmed">33602012</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitsumoto H, Nagy PL, Gennings C, Murphy J, Andrews H, Goetz R, et al. Phenotypic and molecular analyses of primary lateral sclerosis. Neurol Genet. 2015 doi: 10.1212/01.NXG.0000464294.88607.dd.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.NXG.0000464294.88607.dd</ArticleId><ArticleId IdType="pmc">PMC4821084</ArticleId><ArticleId IdType="pubmed">27066542</ArticleId></ArticleIdList></Reference><Reference><Citation>Stone EJ, Kolb SJ, Brown A. A review and analysis of the clinical literature on Charcot&#x2013;Marie&#x2013;Tooth disease caused by mutations in neurofilament protein L. Cytoskeleton. 2021;78:97&#x2013;110. doi: 10.1002/cm.21676.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cm.21676</ArticleId><ArticleId IdType="pmc">PMC10174713</ArticleId><ArticleId IdType="pubmed">33993654</ArticleId></ArticleIdList></Reference><Reference><Citation>Mul K, Schouten MI, van der Looij E, Dooijes D, Hennekam FAM, Notermans NC, et al. A hereditary spastic paraplegia predominant phenotype caused by variants in the NEFL gene. Parkinsonism Relat Disord. 2020;80:98&#x2013;101. doi: 10.1016/j.parkreldis.2020.09.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.parkreldis.2020.09.016</ArticleId><ArticleId IdType="pubmed">32979786</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks BR, Miller RG, Swash M, Munsat TL. El Escorial revisited: Revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2000;1:293&#x2013;299. doi: 10.1080/146608200300079536.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/146608200300079536</ArticleId><ArticleId IdType="pubmed">11464847</ArticleId></ArticleIdList></Reference><Reference><Citation>Fink JK. Progressive spastic paraparesis: hereditary spastic paraplegia and its relation to primary and amyotrophic lateral sclerosis. Semin Neurol. 2001;21:199&#x2013;207. doi: 10.1055/s-2001-15265.</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-2001-15265</ArticleId><ArticleId IdType="pubmed">11442328</ArticleId></ArticleIdList></Reference><Reference><Citation>Klebe S, Stolze H, Kopper F, Lorenz D, Wenzelburger R, Volkmann J, et al. Gait analysis of sporadic and hereditary spastic paraplegia. J Neurol. 2004;251:571&#x2013;578. doi: 10.1007/s00415-004-0366-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-004-0366-7</ArticleId><ArticleId IdType="pubmed">15164190</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi Y, Wang A, Chen B, Wang X, Niu S, Li W, et al. Clinical features and genetic spectrum of patients with clinically suspected hereditary progressive spastic paraplegia. Front Neurol. 2022;13:1&#x2013;13. doi: 10.3389/fneur.2022.872927.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2022.872927</ArticleId><ArticleId IdType="pmc">PMC9097539</ArticleId><ArticleId IdType="pubmed">35572931</ArticleId></ArticleIdList></Reference><Reference><Citation>Brugman F, Veldink JH, Franssen H, De Visser M, Vianney-de-Jong JMB, Faber CG, et al. Differentiation of hereditary spastic paraparesis from primary lateral sclerosis in sporadic adult-onset upper motor neuron syndromes. Arch Neurol. 2009;66:509&#x2013;514. doi: 10.1001/archneurol.2009.19.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneurol.2009.19</ArticleId><ArticleId IdType="pubmed">19364936</ArticleId></ArticleIdList></Reference><Reference><Citation>de Vries BS, Rustemeijer LMM, van der Kooi AJ, Raaphorst J, Schr&#xf6;der CD, Nijboer TCW, et al. A case series of PLS patients with frontotemporal dementia and overview of the literature. Amyotroph Lateral Scler Frontotemporal Degener. 2017;18:534&#x2013;548. doi: 10.1080/21678421.2017.1354996.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2017.1354996</ArticleId><ArticleId IdType="pubmed">28745069</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackenzie IRA, Briemberg H. TDP-43 pathology in primary lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2020;21:52&#x2013;58. doi: 10.1080/21678421.2020.1790607.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2020.1790607</ArticleId><ArticleId IdType="pubmed">32657153</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>